losartan and Cirrhosis studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

Excerpt	Relevance	Reference
" We hypothesized that the angiotensin receptor blocker (ARB) losartan would reduce inflammation by mitigating nuclear factor (NF)κB responses and promote T-cell recovery via inhibition of transforming growth factor-beta (TGFβ)-mediated fibrosis."	9.41	Losartan to reduce inflammation and fibrosis endpoints in HIV disease. ( Baker, JV; Collins, G; Deeks, S; Liappis, AP; Morse, C; Mystakelis, H; Neaton, J; Rhame, F; Rizza, S; Schacker, T; Sereti, I; Temesgen, Z; Tracy, RP; Wolfson, J, 2021)
"Losartan had no effect on lymphoid fibrosis or immune activation/inflammation."	9.41	Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. ( Caballero, M; Diaz, A; Fabra, A; Garcia, F; Gatell, JM; Guardo, AC; Leal, L; Plana, M; Squarcia, M; Torres, B; Ugarte, A, 2021)
"The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM)."	9.17	Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. ( Abbara, S; Baggish, AL; Fifer, MA; Ghoshhajra, BB; Ho, CY; Januzzi, JL; Lowry, PA; O'Callaghan, C; Passeri, JJ; Rothman, RD; Seidman, CE; Shimada, YJ; Yannekis, G, 2013)
"A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress."	8.83	Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006)
" Unilateral ureteral obstruction (UUO) renal fibrosis model was established in mice by ligating the left ureter, and then randomly received losartan at a low dose (1 mg/kg) or a regular dose (3 mg/kg) for 2 weeks."	8.31	Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. ( Gu, W; Huang, Z; Li, P; Li, TS; Liu, G; Nie, H; Peng, YH; Xiao, J, 2023)
"The purpose of this study was to examine the effect of topical and/or oral angiotensin converting enzyme II inhibitor and TGF-beta signaling blocker losartan on corneal stromal fibrosis that developed in rabbit corneas after Descemetorhexis removal of central Descemet's membrane and corneal endothelium."	8.12	Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. ( Hilgert, GSL; Murillo, SE; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats."	8.12	Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022)
"To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits."	8.12	Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"To study the effect of topical losartan compared to vehicle on the generation of myofibroblasts and development of late haze scarring fibrosis after photorefractive keratectomy (PRK) in rabbits."	8.12	Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"To investigate the effect of losartan on preventing bladder fibrosis and protecting renal function in rats with neurogenic paralysis bladder (NPB)."	8.02	Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder. ( Bauer, SB; Chen, Y; He, YL; Ji, FP; Liu, EP; Ma, Y; Pu, QS; Wang, QW; Wang, Y; Wen, JG; Wen, YB; Xing, D; Yang, XH; Zhai, RQ, 2021)
"In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)."	8.02	Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021)
" We herein examined the effect of EHP-101 on cardiac and other organ fibrosis in a mouse model induced by Angiotensin II."	8.02	EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. ( Appendino, G; Caprioglio, D; García-Martín, A; Garrido-Rodríguez, M; Muñoz, E; Navarrete, C; Prados, ME, 2021)
" The aim of this study is to explore the renal fibrosis and investigate the effect of losartan on renal fibrosis after the obstruction' relief using an improved mouse model of relief for unilateral ureteral obstruction (RUUO)."	7.91	Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs. ( Jiang, C; Luo, J; Shi, GP; Song, J; Xia, Y; Yan, X; Zhang, M; Zhu, W, 2019)
"Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)."	7.91	Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019)
"Prehypertensive losartan treatment may lead to long‑term inhibition of the development of left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs)."	7.85	Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats. ( Lian, GL; Lin, X; Wang, HJ; Wang, TJ; Xie, LD; Xu, CS; Zhong, HB, 2017)
" Losartan stabilized all of these parameters and hindered the progression of fibrosis, but it did not reverse the pre-existing fibrotic manifestations."	7.81	Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015)
"Liver regeneration, expected to decrease on day 3, was prolonged and increased even on day 5 despite antiangiogenic effects of Losartan and Spironolactone, which in fact inhibit fibrosis through phospho-Smad2 and increase regeneration."	7.79	Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation. ( Calıskan, K; Colakoglu, S; Colakoglu, T; Ezer, A; Karakaya, J; Kayaselcuk, F; Parlakgumus, A; Yildirim, S, 2013)
"This study examined the antifibrotic effect of losartan, an angiotensin II type 1 receptor antagonist, in an animal model of heart fibrosis induced by long-term intense exercise."	7.79	Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. ( Benito, B; Brugada, J; Gay-Jordi, G; Guash, E; Mont, L; Nattel, S; Serrano-Mollar, A, 2013)
"To evaluate the in vivo effect of losartan - an angiotensin II receptor antagonist - on the course of chronic colitis-associated fibrosis and on TGF-b1 expression."	7.78	Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. ( Goldin, E; Israeli, E; Latella, G; Lysy, J; Metanes, I; Necozione, S; Papo, O; Pines, M; Wengrower, D; Zanninelli, G, 2012)
"Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model."	7.78	The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. ( Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012)
"This study investigated the effects of losartan intervention on the expressions of hypoxia-inducible factor-1α (HIF-1α), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in renal fibrosis in rats with 5/6 nephrectomy."	7.78	Losartan alleviates renal fibrosis by down-regulating HIF-1α and up-regulating MMP-9/TIMP-1 in rats with 5/6 nephrectomy. ( Cheng, W; Fu, W; Jin, Z; Peng, W; Wang, H; Wang, Y; Yin, P; Zhou, H, 2012)
"To determine the role of angiotensin II (Ang II)/Ang II type 1 (AT(1)) receptor-coupled transforming growth factor (TGF)-β(1)/Smad signaling pathway in the AF-induced atrial fibrosis."	7.77	Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. ( Duan, DD; Gao, X; He, X; Lin, J; Ma, H; Peng, L; Wang, S; Zhu, Y, 2011)
"To investigate the effect of losartan on the expression of monocyte chemoattractant protein-1 (MCP1) and transforming growth factor-β(1) (TGF-β(1)) in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate protective effect of losartan against reanal interstitial fibrosis."	7.77	[Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction]. ( Du, H; Fu, JZ; Huang, YY; Xu, AP; Zhou, SS, 2011)
"Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR."	7.74	[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008)
" We have investigated the effects of a long-acting calcium antagonist, benidipine, and an angiotensin AT(1) receptor antagonist, losartan, on the vascular damage observed in OLETF rats, an animal model of metabolic syndrome."	7.74	Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. ( Furuta, K; Hongo, M; Ishizaka, N; Koike, K; Matsuzaki, G; Nagai, R; Saito, K; Sakurai, R, 2008)
" The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)."	7.73	Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005)
"Angiotensin II (Ang II) participates in the development of fibrosis during vascular damage."	7.72	Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. ( Blanco-Colio, LM; Egido, J; Esteban, V; Lorenzo, O; Ruiz-Ortega, M; Rupérez, M, 2003)
"This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)."	7.72	[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004)
"Losartan prevents apoptosis of pancreatic acinar cell by blocking AT1R during the development of pancreatic fibrosis."	7.72	Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R. ( Dong, Y; Wang, XP; Wu, K; Wu, L; Zhang, R, 2004)
"We divided 2-month-old male Sprague-Dawley rats into 4 groups, namely group 1-control, group 2-hyperoxaluria, group 3-hyperoxaluria plus losartan and group 4-losartan."	7.71	Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. ( Angerosa, M; De Cavanaugh, EM; Ferder, L; Inserra, F; Stella, I; Toblli, JE, 2002)
"Cardiac iron deposition may be involved in the development of cardiac fibrosis induced by angiotensin II."	7.71	Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. ( Ishizaka, N; Mitani, H; Mori, I; Nagai, R; Ohno, M; Saito, K; Sata, M; Usui, S; Yamazaki, I, 2002)
"To investigate the different effects of an angiotensin II type 1 (AT(1)) receptor antagonist, losartan, and an angiotensin converting enzyme (ACE) inhibitor, fosinopril, on cardiomyocyte apoptosis, myocardial fibrosis, and angiotensin II (Ang II) in the left ventricle of spontaneously hypertensive rats (SHRs)."	7.71	Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. ( Liang, X; Sun, M; Xie, X; Yang, T; Yu, G; Zhao, S, 2002)
"To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR)."	7.71	[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. ( He, BX; Liang, XQ; Yu, GL, 2001)
"In cirrhotic patients without ascites, creatinine clearance, 24-h urinary sodium excretion, and fractional excretion of sodium were significantly increased after losartan administration."	7.71	One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. ( Chang, FY; Hou, MC; Lee, FY; Lee, SD; Lee, WC; Lin, HC; Yang, YY, 2002)
" To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)."	7.70	Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998)
"There was (1) low angiotensin receptor binding in normal myocardium; (2) markedly increased angiotensin II receptor binding at the site of left ventricular myocardial infarction and endocardial fibrosis of the interventricular septum at day 3 and weeks 1, 2, 4, and 8; (3) high angiotensin II receptor binding in the pericardial fibrosis that followed pericardiotomy, and in the fibrosis that appeared in response to suture insertion around the left coronary artery, in both infarcted and sham operated rats; (4) total displacement of normal and connective tissue angiotensin II receptor binding by DuP753, but not by PD123177; (5) ACE inhibition by lisinopril, but no change in angiotensin II receptor binding, at all sites of fibrosis; and (6) significant attenuation by lisinopril of collagen formation in the visceral pericardium of sham operated controls."	7.69	Angiotensin II receptor binding following myocardial infarction in the rat. ( Sun, Y; Weber, KT, 1994)
"Losartan is an angiotensin II receptor blocker (ARB) that impedes transforming growth factor (TGF) beta signaling by inhibiting activation of signal transduction molecule extracellular signal-regulated kinase (ERK)."	7.01	Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. ( Wilson, SE, 2023)
"In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis."	6.71	Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004)
"Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)."	6.71	Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005)
"Losartan is a typical Angiotensin II (ANG II) receptor antagonist and relaxes blood vessels."	5.72	Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. ( Ma, Y; Yu, R; Zhou, X; Zou, J, 2022)
"Cardiac fibrosis is a severe condition with limited therapeutic options and often occurs in chronic cardiovascular diseases such as hypertension and myocardial infarction."	5.72	Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis. ( Chen, W; Han, L; Ji, H; Yu, L; Zhu, H, 2022)
"Losartan is an inhibitor of transforming growth factor-β signaling."	5.72	Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. ( Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022)
"Losartan shows minimal adverse effects and no influence on graft function and biomarkers of graft fibrosis."	5.51	Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients. ( Biedunkiewicz, B; Chamienia, A; Dębska-Ślizień, A; Głyda, M; Heleniak, Z; Konopa, J; Kuźmiuk-Glembin, I; Lizakowski, S; Pięta, R; Renke, M; Rutkowski, B; Tylicki, L, 2022)
"Pleural fibrosis is associated with various inflammatory processes such as tuberculous pleurisy and bacterial empyema."	5.48	Inhibition of angiotensin II and calpain attenuates pleural fibrosis. ( Greer, PA; Huang, H; Ma, WL; Shi, HZ; Song, LJ; Su, Y; Xiang, F; Xin, JB; Xiong, L; Xu, JJ; Yang, J; Ye, H; Yu, F, 2018)
" We hypothesized that the angiotensin receptor blocker (ARB) losartan would reduce inflammation by mitigating nuclear factor (NF)κB responses and promote T-cell recovery via inhibition of transforming growth factor-beta (TGFβ)-mediated fibrosis."	5.41	Losartan to reduce inflammation and fibrosis endpoints in HIV disease. ( Baker, JV; Collins, G; Deeks, S; Liappis, AP; Morse, C; Mystakelis, H; Neaton, J; Rhame, F; Rizza, S; Schacker, T; Sereti, I; Temesgen, Z; Tracy, RP; Wolfson, J, 2021)
"Losartan had no effect on lymphoid fibrosis or immune activation/inflammation."	5.41	Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. ( Caballero, M; Diaz, A; Fabra, A; Garcia, F; Gatell, JM; Guardo, AC; Leal, L; Plana, M; Squarcia, M; Torres, B; Ugarte, A, 2021)
"Losartan treatment partially attenuated these responses."	5.40	Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014)
"Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy."	5.40	Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014)
"Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice."	5.37	Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. ( Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q, 2011)
"Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin."	5.36	Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. ( Neuschwander-Tetri, BA; Oshima, K; Talkad, V; Ulmasov, B; Xu, Z, 2010)
"Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0."	5.36	Losartan reduces mortality in a genetic model of heart failure. ( Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010)
"Losartan pretreated-rats presented diminished FN abundance in homogenates of cortex tissue from ischemic rats with or without reperfusion."	5.32	Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. ( Barrilli, A; Elías, MM; Menacho, M; Molinas, S; Petrini, G, 2004)
"Tubulointerstitial fibrosis is considered to be common endpoint result of many forms of chronic renal diseases."	5.31	Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. ( Dai, C; Liu, Y; Yang, J, 2002)
"Aldosterone levels were not significantly elevated, suggesting direct proliferative effects of Ang II."	5.30	Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. ( Gray, GA; Kenyon, CJ; McEwan, PE; Sherry, L; Webb, DJ, 1998)
"Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure."	5.29	Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995)
"Losartan treatment decreased the tissue expression of miR-21 and TGF-β and tissue fibrosis in kidney transplant patient, and it had a protective effect on allograft function and may delay chronic allograft dysfunction by reducing mediators of fibrosis."	5.27	Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers. ( Nafar, M; Samavat, S; Shahraki, E, 2018)
" The aim of this randomised controlled trial was to assess whether treatment with Losartan for 96 weeks slowed, halted or reversed the progression of fibrosis in patients with non-alcoholic steatohepatitis (NASH)."	5.24	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. ( Anstee, QM; Barnes, J; Burt, AD; Bury, Y; Day, CP; Goudie, N; Mann, D; McColl, E; McPherson, S; Steen, N; Stewart, S; Stocken, DD; Tiniakos, D; Wilkinson, J; Wilkinson, N, 2017)
"The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM)."	5.17	Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. ( Abbara, S; Baggish, AL; Fifer, MA; Ghoshhajra, BB; Ho, CY; Januzzi, JL; Lowry, PA; O'Callaghan, C; Passeri, JJ; Rothman, RD; Seidman, CE; Shimada, YJ; Yannekis, G, 2013)
"To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy."	5.16	Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012)
"In 204 patients with hypertension and left ventricular (LV) hypertrophy we measured serum concentration of carboxy-terminal telopeptide of type I procollagen (ICTP), carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), amino-terminal propeptide of type I procollagen (PINP) and LV mass by echocardiography at baseline and annually during 4 years of losartan- or atenolol-based antihypertensive treatment; 185 patients completed the study."	5.12	Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. ( Bang, LE; Christensen, MK; Devereux, RB; Fossum, E; Hildebrandt, P; Ibsen, H; Kjeldsen, SE; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K; Wiinberg, N, 2006)
" Inhibition of TGFβ signaling by Losartan treatment greatly improved the phenotype of myopathies associated with laminin-α2-deficient congenital muscular dystrophy."	4.88	TGFβ signaling: its role in fibrosis formation and myopathies. ( Cohn, RD; MacDonald, EM, 2012)
"A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress."	4.83	Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006)
" THC was administered via daily oral gavage with the lipid carrier polyenylphosphatidylcholine (PPC) as add-on therapy to losartan (angiotensin receptor blocker) to examine effects on kidney oxidative stress and fibrosis."	4.31	Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. ( Khazaali, M; Khazaeli, M; Lau, WL; Nunes, ACF; Prudente, J; Singh, B; Vaziri, ND; Zhao, Y, 2023)
" We studied the effect of a hybrid compound, GGN1231 (derived from losartan in which a powerful antioxidant was attached), on the prevention of cardiovascular damage, cardiac hypertrophy, and fibrosis in a rat model of severe chronic renal failure (CRF)."	4.31	Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure. ( Alajarín, R; Alonso-Montes, C; Alvarez-Builla, J; Cannata-Andía, JB; Carrillo-López, N; Fernández-Villabrille, S; García-Navazo, G; Gutiérrez-Calabres, E; Martínez-Arias, L; Naves-Díaz, M; Panizo, S; Rodríguez-Puyol, D; Ruíz-Torres, MP; Vaquero-López, JJ, 2023)
"Male cardiac-specific BACH1 knockout mice or cardiac-specific BACH1 transgenic (BACH1-Tg) mice and their respective wild-type littermates developed cardiac hypertrophy induced by angiotensin II (Ang II) or transverse aortic constriction (TAC)."	4.31	Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway. ( Chen, L; Ge, F; Guo, J; He, Y; Hu, K; Jia, M; Jiang, L; Jin, J; Li, L; Li, Q; Lv, X; Ma, S; Meng, D; Osto, E; Wang, X; Wei, X; Wu, H; Wu, J; Yang, Z; Zhang, J; Zhi, X, 2023)
" Unilateral ureteral obstruction (UUO) renal fibrosis model was established in mice by ligating the left ureter, and then randomly received losartan at a low dose (1 mg/kg) or a regular dose (3 mg/kg) for 2 weeks."	4.31	Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. ( Gu, W; Huang, Z; Li, P; Li, TS; Liu, G; Nie, H; Peng, YH; Xiao, J, 2023)
"The purpose of this study was to examine the effect of topical and/or oral angiotensin converting enzyme II inhibitor and TGF-beta signaling blocker losartan on corneal stromal fibrosis that developed in rabbit corneas after Descemetorhexis removal of central Descemet's membrane and corneal endothelium."	4.12	Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. ( Hilgert, GSL; Murillo, SE; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats."	4.12	Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022)
"To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits."	4.12	Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"To study the effect of topical losartan compared to vehicle on the generation of myofibroblasts and development of late haze scarring fibrosis after photorefractive keratectomy (PRK) in rabbits."	4.12	Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
" Similar to losartan, Dojuksan ameliorated kidney inflammation and fibrosis in UUO mice."	4.02	Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk. ( Dorotea, D; Ha, H; Jiang, S; Kim, DS; Oh, DS; Son, E, 2021)
"To investigate the effect of losartan on preventing bladder fibrosis and protecting renal function in rats with neurogenic paralysis bladder (NPB)."	4.02	Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder. ( Bauer, SB; Chen, Y; He, YL; Ji, FP; Liu, EP; Ma, Y; Pu, QS; Wang, QW; Wang, Y; Wen, JG; Wen, YB; Xing, D; Yang, XH; Zhai, RQ, 2021)
"In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)."	4.02	Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021)
" We herein examined the effect of EHP-101 on cardiac and other organ fibrosis in a mouse model induced by Angiotensin II."	4.02	EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. ( Appendino, G; Caprioglio, D; García-Martín, A; Garrido-Rodríguez, M; Muñoz, E; Navarrete, C; Prados, ME, 2021)
" Delayed exercise after complex orthopaedic trauma results in decreased muscle fibrosis and improved pain Losartan, an angiotensin-receptor blocker with anti-fibrotic abilities, recapitulates the effect of exercise on post-injury recovery and may provide an enhanced recovery option for those who are unable to exercise after injury ABSTRACT: Chronic pain and disability after limb injury are major public health problems."	3.96	Angiotensin receptor blockade mimics the effect of exercise on recovery after orthopaedic trauma by decreasing pain and improving muscle regeneration. ( Clark, JD; Forman, TE; Goodman, SB; Paine, P; Pajarinen, J; Quarta, M; Rando, TA; Takemura, Y; Tawfik, VL, 2020)
"It has been described that the cardiac dysfunction in the obesity model is because of collagen imbalance and that angiotensin II (Ang II) contributes to myocardial fibrosis."	3.96	Increased angiotensin II from adipose tissue modulates myocardial collagen I and III in obese rats. ( Cicogna, AC; Corrêa, CR; da Silva-Bertani, DCT; de Oliveira, EM; de Souza, SLB; de Tomasi, LC; Fernandes, T; Freire, PP; Mota, GAF; Padovani, CR; Sant'Ana, PG; Vileigas, DF, 2020)
" The aim of this study is to explore the renal fibrosis and investigate the effect of losartan on renal fibrosis after the obstruction' relief using an improved mouse model of relief for unilateral ureteral obstruction (RUUO)."	3.91	Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs. ( Jiang, C; Luo, J; Shi, GP; Song, J; Xia, Y; Yan, X; Zhang, M; Zhu, W, 2019)
"Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)."	3.91	Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019)
" We test such interactions in the brain and cerebral vessels of TGF mice by measuring cerebrovascular reactivity, levels of protein markers of vascular fibrosis, nitric oxide synthase activity, astrogliosis, and mnemonic performance in mice treated (6 months) with the AT1R blocker losartan (10 mg/kg per day) or the angiotensin converting enzyme inhibitor enalapril (3 mg/kg per day)."	3.88	Transforming growth factor-β1 induces cerebrovascular dysfunction and astrogliosis through angiotensin II type 1 receptor-mediated signaling pathways. ( Hamel, E; Imboden, H; Lecrux, C; Nicolakakis, N; Ongali, B; Tong, XK, 2018)
"Angiotensin II (Ang II) has been regarded as an important profibrogenic cytokine in renal fibrosis."	3.85	KLF 15 Works as an Early Anti-Fibrotic Transcriptional Regulator in Ang II-Induced Renal Fibrosis via Down-Regulation of CTGF Expression. ( Fu, L; Gao, X; Gu, X; Mei, C; Wang, Y; Xu, D, 2017)
"Prehypertensive losartan treatment may lead to long‑term inhibition of the development of left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs)."	3.85	Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats. ( Lian, GL; Lin, X; Wang, HJ; Wang, TJ; Xie, LD; Xu, CS; Zhong, HB, 2017)
" The angiotensin II antagonist losartan, metabolized to the EXP3179 and EXP3174 metabolites, reduces myocardial fibrosis and LV stiffness in hypertensive patients."	3.85	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. ( Beaumont, J; Díez, J; Fortuño, A; González, A; López, B; Miguel-Carrasco, JL; Moreno, MU; Ravassa, S; San José, G; Zalba, G, 2017)
"Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart."	3.85	Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017)
" Losartan stabilized all of these parameters and hindered the progression of fibrosis, but it did not reverse the pre-existing fibrotic manifestations."	3.81	Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015)
"To elucidate the reliability of MRI as a non-invasive tool for assessing in vivo muscle health and pathological amelioration in response to Losartan (Angiotensin II Type 1 receptor blocker) in DyW mice (mouse model for Laminin-deficient Congenital Muscular Dystrophy Type 1A)."	3.81	Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). ( Accorsi, A; Girgenrath, M; Kumar, A; Vohra, R; Walter, G, 2015)
"The aim of this study was to evaluate the effect of compound 21 (C21), a selective AT2 receptor agonist, on diabetic nephropathy and the potential additive effect of C21, when associated with losartan treatment, on the development of albuminuria and renal fibrosis in Zucker diabetic fatty (ZDF) rats."	3.80	Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. ( Bombardi, C; Carletti, R; Castoldi, G; Dahlöf, B; di Gioia, CR; Maestroni, S; Steckelings, UM; Stella, A; Unger, T; Zerbini, G, 2014)
"Liver regeneration, expected to decrease on day 3, was prolonged and increased even on day 5 despite antiangiogenic effects of Losartan and Spironolactone, which in fact inhibit fibrosis through phospho-Smad2 and increase regeneration."	3.79	Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation. ( Calıskan, K; Colakoglu, S; Colakoglu, T; Ezer, A; Karakaya, J; Kayaselcuk, F; Parlakgumus, A; Yildirim, S, 2013)
"This study examined the antifibrotic effect of losartan, an angiotensin II type 1 receptor antagonist, in an animal model of heart fibrosis induced by long-term intense exercise."	3.79	Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. ( Benito, B; Brugada, J; Gay-Jordi, G; Guash, E; Mont, L; Nattel, S; Serrano-Mollar, A, 2013)
"To evaluate the in vivo effect of losartan - an angiotensin II receptor antagonist - on the course of chronic colitis-associated fibrosis and on TGF-b1 expression."	3.78	Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. ( Goldin, E; Israeli, E; Latella, G; Lysy, J; Metanes, I; Necozione, S; Papo, O; Pines, M; Wengrower, D; Zanninelli, G, 2012)
"100 healthy Sprague-Dawley rats were randomly divided into 5 groups: Unilateral ureteral obstruction (UUO) group, sham-operation (SOR) group, Radix Notoginseng (RN) group, compound Radix Notoginseng (CRN) group and Losartan (ARB) group."	3.78	[Investigate the effects of compound radix notoginseng on renal interstitial fibrosis and kidney-targeting treatment]. ( Fan, JM; Feng, SG; Liu, HC; Xie, XS; Yuan, W; Zhang, CL; Zhang, ZY; Zuo, C, 2012)
" Losartan significantly attenuated the expression of TGF-β1 and Snail, and decreased kidney fibrosis induced by IS and PCS in vivo."	3.78	Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. ( Chang, SC; Sun, CY; Wu, MS, 2012)
"The activation of transforming growth factor-β1(TGF-β1)/Smad signaling pathway and increased expression of connective tissue growth factor (CTGF) induced by angiotensin II (AngII) have been proposed as a mechanism for atrial fibrosis."	3.78	Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. ( Gu, J; Guo, M; Jiang, WF; Liu, X; Tan, HW; Wang, QX; Zhou, L, 2012)
"Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model."	3.78	The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. ( Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012)
"This study investigated the effects of losartan intervention on the expressions of hypoxia-inducible factor-1α (HIF-1α), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in renal fibrosis in rats with 5/6 nephrectomy."	3.78	Losartan alleviates renal fibrosis by down-regulating HIF-1α and up-regulating MMP-9/TIMP-1 in rats with 5/6 nephrectomy. ( Cheng, W; Fu, W; Jin, Z; Peng, W; Wang, H; Wang, Y; Yin, P; Zhou, H, 2012)
"To determine the role of angiotensin II (Ang II)/Ang II type 1 (AT(1)) receptor-coupled transforming growth factor (TGF)-β(1)/Smad signaling pathway in the AF-induced atrial fibrosis."	3.77	Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. ( Duan, DD; Gao, X; He, X; Lin, J; Ma, H; Peng, L; Wang, S; Zhu, Y, 2011)
" The aim of this work was to assess the impact of hemin (heme oxygenase-1 inducer) on NADPH oxidase activation, cardiac oxidative stress, and development of fibrosis in a rat model of renovascular hypertensive cardiomyopathy in comparison to an anti-hypertensive reference treatment with losartan."	3.77	Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling. ( Belmokhtar, K; Bonnet, P; Eder, V; Khamis, G; Machet, MC; Vourc'h, P; Worou, ME, 2011)
"To investigate the effect of losartan on the expression of monocyte chemoattractant protein-1 (MCP1) and transforming growth factor-β(1) (TGF-β(1)) in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate protective effect of losartan against reanal interstitial fibrosis."	3.77	[Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction]. ( Du, H; Fu, JZ; Huang, YY; Xu, AP; Zhou, SS, 2011)
"Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR."	3.74	[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008)
"The angiotensin converting enzyme inhibitor captopril prevents myosin-induced experimental autoimmune myocarditis."	3.74	Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. ( Bahk, TJ; Daniels, MD; Engman, DM; Leon, JS; Wang, K, 2008)
" We have investigated the effects of a long-acting calcium antagonist, benidipine, and an angiotensin AT(1) receptor antagonist, losartan, on the vascular damage observed in OLETF rats, an animal model of metabolic syndrome."	3.74	Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. ( Furuta, K; Hongo, M; Ishizaka, N; Koike, K; Matsuzaki, G; Nagai, R; Saito, K; Sakurai, R, 2008)
" The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)."	3.73	Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005)
"We examined the effects of combined treatment with SMP-534 and losartan on urinary albumin and glomerular fibrosis in db/db mice."	3.73	Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2006)
"Rats underwent unilateral ureteral obstruction and were given either drinking water or losartan for 21 days."	3.73	Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. ( Chen, J; El Chaar, M; Felsen, D; Kellner, D; Poppas, D; Richardson, I; Seshan, SV; Vaughan, ED, 2006)
"The influence of chronic administration of losartan on gap junction conductance (gj), conduction velocity and interstitial fibrosis was investigated in the failing heart of 4-month-old cardiomyopathic hamsters (TO-2)."	3.73	Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart. ( De Mello, WC; Specht, P, 2006)
"Angiotensin II (Ang II) participates in the development of fibrosis during vascular damage."	3.72	Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. ( Blanco-Colio, LM; Egido, J; Esteban, V; Lorenzo, O; Ruiz-Ortega, M; Rupérez, M, 2003)
"This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)."	3.72	[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004)
" We examined the effect of an angiotensin II receptor inhibitor (AT(1)) losartan, independent from its effects on blood pressure, on nitric oxide synthase (NOS) isoforms and cyclooxygenase-2 (COX-2) expression and the significance of this interaction on interstitial fibrosis in UUO."	3.72	Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. ( Carrizo, L; Manucha, W; Oliveros, L; Seltzer, A; Vallés, P, 2004)
"Losartan prevents apoptosis of pancreatic acinar cell by blocking AT1R during the development of pancreatic fibrosis."	3.72	Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R. ( Dong, Y; Wang, XP; Wu, K; Wu, L; Zhang, R, 2004)
"We divided 2-month-old male Sprague-Dawley rats into 4 groups, namely group 1-control, group 2-hyperoxaluria, group 3-hyperoxaluria plus losartan and group 4-losartan."	3.71	Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. ( Angerosa, M; De Cavanaugh, EM; Ferder, L; Inserra, F; Stella, I; Toblli, JE, 2002)
"Cardiac iron deposition may be involved in the development of cardiac fibrosis induced by angiotensin II."	3.71	Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. ( Ishizaka, N; Mitani, H; Mori, I; Nagai, R; Ohno, M; Saito, K; Sata, M; Usui, S; Yamazaki, I, 2002)
"To investigate the different effects of an angiotensin II type 1 (AT(1)) receptor antagonist, losartan, and an angiotensin converting enzyme (ACE) inhibitor, fosinopril, on cardiomyocyte apoptosis, myocardial fibrosis, and angiotensin II (Ang II) in the left ventricle of spontaneously hypertensive rats (SHRs)."	3.71	Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. ( Liang, X; Sun, M; Xie, X; Yang, T; Yu, G; Zhao, S, 2002)
"To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR)."	3.71	[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. ( He, BX; Liang, XQ; Yu, GL, 2001)
"We randomized 24 adult cardiac troponin T (cTnT-Q(92)) mice, which exhibit myocyte disarray and interstitial fibrosis, to treatment with losartan or placebo and included 12 nontransgenic mice as controls."	3.71	Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. ( Bachireddy, P; Entman, M; Evans, A; Lim, DS; Lutucuta, S; Marian, AJ; Roberts, R; Youker, K, 2001)
"Compared with the fibrosis in rats of the model group, rats treated with either enalapril or losartan, or a combination of two drugs, showed a limited expansion of the interstitium (P < 0."	3.71	The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4. ( Huang, X; Li, D; Lu, H; Wang, Z; Wei, H; Zhan, Y, 2001)
" The effect of the angiotensin II type 1 receptor antagonist, losartan (10 mg x kg(-1) x d(-1))on aldosterone-induced cardiac hypertrophy was also studied."	3.71	Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. ( Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T, 2002)
"In cirrhotic patients without ascites, creatinine clearance, 24-h urinary sodium excretion, and fractional excretion of sodium were significantly increased after losartan administration."	3.71	One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. ( Chang, FY; Hou, MC; Lee, FY; Lee, SD; Lee, WC; Lin, HC; Yang, YY, 2002)
" To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)."	3.70	Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998)
"Angiotensin II (Ang II) has been shown to be implicated in the development of renal fibrosis in several forms of chronic glomerulonephritides, but the precise mechanisms of its effects remain unclear."	3.70	Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. ( Cerullo, G; Colucci, M; Gesualdo, L; Grandaliano, G; Monno, R; Ranieri, E; Rossiello, MR; Schena, FP; Semeraro, N; Ursi, M, 1999)
"Animals were divided into three groups: myocarditis, myocarditis intervened by Losartan, and normal control."	3.70	[Preventional intervention of myocardial interstitial fibrosis in murine myocardium with acute myocarditis]. ( Cheng, X; Jing, Z; Yang, Y, 1998)
"In this study we infused phenylephrine into adult Wistar rats and used losartan to test for a possible role of angiotensin II in the phenylephrine-induced fibrosis."	3.69	Effect of angiotensin II blockade on the fibroproliferative response to phenylephrine in the rat heart. ( Brecher, P; Chobanian, AV; Crawford, DC; Farivar, RS, 1995)
"There was (1) low angiotensin receptor binding in normal myocardium; (2) markedly increased angiotensin II receptor binding at the site of left ventricular myocardial infarction and endocardial fibrosis of the interventricular septum at day 3 and weeks 1, 2, 4, and 8; (3) high angiotensin II receptor binding in the pericardial fibrosis that followed pericardiotomy, and in the fibrosis that appeared in response to suture insertion around the left coronary artery, in both infarcted and sham operated rats; (4) total displacement of normal and connective tissue angiotensin II receptor binding by DuP753, but not by PD123177; (5) ACE inhibition by lisinopril, but no change in angiotensin II receptor binding, at all sites of fibrosis; and (6) significant attenuation by lisinopril of collagen formation in the visceral pericardium of sham operated controls."	3.69	Angiotensin II receptor binding following myocardial infarction in the rat. ( Sun, Y; Weber, KT, 1994)
" Therefore, we investigated the effect of AT1 or AT2 subtype receptor chronic blockade by losartan or PD123319 on the vascular hypertrophy in rats with Ang II-induced hypertension."	3.69	Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. ( Benessiano, J; Caputo, L; Duriez, M; Henrion, D; Heymes, C; Levy, BI; Poitevin, P; Samuel, JL, 1996)
"Losartan is an angiotensin II receptor blocker (ARB) that impedes transforming growth factor (TGF) beta signaling by inhibiting activation of signal transduction molecule extracellular signal-regulated kinase (ERK)."	3.01	Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. ( Wilson, SE, 2023)
"Treatment with losartan was safe, suggesting that it can be used for other indications in patients with hypertrophic cardiomyopathy, irrespective of obstructive physiology."	2.80	Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. ( Ahtarovski, K; Axelsson, A; Bundgaard, H; Corell, P; Havndrup, O; Ho, C; Iversen, K; Jensen, M; Langhoff, L; Norsk, J; Vejlstrup, N, 2015)
"In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis."	2.71	Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004)
"Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)."	2.71	Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005)
"Treatment with losartan (50 mg) was introduced."	2.69	Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. ( Campistol, JM; Clesca, PH; Iñigo, P; Jimenez, W; Lario, S; Oppenheimer, F; Rivera, F, 1999)
"Transforming growth factor beta 1 is a key molecule in the development of postoperative fibrosis."	2.58	Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation. ( Bolia, I; Briggs, K; Huard, J; Lowe, WR; Philippon, MJ; Utsunomiya, H, 2018)
"Rotator cuff repair combined with oral losartan and BMS of the greater tuberosity showed improved pullout strength and a highly organized tendon matrix in this rabbit chronic injury model."	1.91	Losartan in Combination With Bone Marrow Stimulation Showed Synergistic Effects on Load to Failure and Tendon Matrix Organization in a Rabbit Model. ( Altintas, B; Dornan, G; Fukase, N; Gao, X; Huard, J; Kashyap, R; Lacheta, L; Miles, JW; Millett, PJ; Murata, Y; Philippon, M; Ravuri, S; Tashman, S; Utsunomiya, H, 2023)
"Losartan is a typical Angiotensin II (ANG II) receptor antagonist and relaxes blood vessels."	1.72	Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. ( Ma, Y; Yu, R; Zhou, X; Zou, J, 2022)
"Cardiac fibrosis is a severe condition with limited therapeutic options and often occurs in chronic cardiovascular diseases such as hypertension and myocardial infarction."	1.72	Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis. ( Chen, W; Han, L; Ji, H; Yu, L; Zhu, H, 2022)
"Losartan is an inhibitor of transforming growth factor-β signaling."	1.72	Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. ( Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022)
"Pleural fibrosis is associated with various inflammatory processes such as tuberculous pleurisy and bacterial empyema."	1.48	Inhibition of angiotensin II and calpain attenuates pleural fibrosis. ( Greer, PA; Huang, H; Ma, WL; Shi, HZ; Song, LJ; Su, Y; Xiang, F; Xin, JB; Xiong, L; Xu, JJ; Yang, J; Ye, H; Yu, F, 2018)
"Losartan treatment for three weeks lowered systolic blood pressure in both Control and Restricted groups but this difference was not sustained after the cessation of treatment."	1.48	Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health. ( Gallo, LA; Mazzuca, MQ; Moritz, KM; Parkington, HC; Tare, M; Walton, SL; Wlodek, ME, 2018)
"Treatment with losartan reduced left ventricular dysfunction and prevented increased extracellular volume fraction, indicating that T1 mapping is sensitive to pharmacological prevention of fibrosis."	1.40	T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. ( Fiedler, LR; Gsell, W; Habib, J; McSweeney, SJ; Prasad, SK; Price, AN; Schneider, MD; Stuckey, DJ; Thin, MZ, 2014)
"Losartan treatment partially attenuated these responses."	1.40	Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014)
"Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy."	1.40	Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014)
"AKF-PD was used to treat renal fibrosis in unilateral ureteral obstruction (UUO) obstructive nephropathy in rats."	1.39	Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. ( Cheng, GJ; Hu, GY; Huang, L; Mei, WJ; Peng, ZZ; Qin, J; Tao, LJ; Xie, YY; Yuan, QJ; Yuan, XN, 2013)
"Losartan treatment reduced the fibrosis in the CC UUO kidneys."	1.38	Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. ( Brazin, JA; Chen, J; Estephan, R; Felsen, D; Kameue, T; Maack, T; Mora, R; O'Connor, N; Poppas, DP; Reid, AC; Seshan, SV; Silver, RB; Veerappan, A, 2012)
"Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice."	1.37	Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. ( Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q, 2011)
"Fibrosis was evaluated in the diaphragm and heart by Trichrome stain and by determination of tissue hydroxyproline content."	1.37	Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. ( Acosta, P; Barton, ER; Bish, LT; Gazzara, JA; Morine, KJ; Sleeper, MM; Sweeney, HL; Yarchoan, M, 2011)
"Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin."	1.36	Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. ( Neuschwander-Tetri, BA; Oshima, K; Talkad, V; Ulmasov, B; Xu, Z, 2010)
"Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart."	1.36	Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010)
"Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0."	1.36	Losartan reduces mortality in a genetic model of heart failure. ( Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010)
"Losartan treatment did not reverse pathologic remodeling of established HCM but did reduce non-myocyte proliferation."	1.36	Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. ( Alcalai, R; Eminaga, S; Gorham, JM; Hoffman, SR; Kim, JB; Konno, T; Markwald, RR; Molkentin, JD; Nayor, M; Norris, RA; Schmitt, JP; Seidman, CE; Seidman, JG; Tager, AM; Teekakirikul, P; Toka, O; Wakimoto, H; Wang, L; Wolf, CM, 2010)
"Losartan treatment resulted in improvement of myocardial function and suppressed cardiac and renal fibrosis compared with the diabetic group."	1.35	Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. ( Aizawa, Y; Arozal, W; Kodama, M; Ma, M; Suzuki, K; Tachikawa, H; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K, 2009)
"RV hypertrophy was also prevented, but LV hypertrophy only partially, and kidney hypertrophy not at all."	1.35	Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. ( Leenen, FH; Liang, B, 2008)
"Diabetic nephropathy is the main cause of end-stage renal disease."	1.34	Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2007)
"Aldosterone plays a key role in the pathogenesis of Ang II-induced organ damage."	1.33	Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. ( Al-Saadi, N; Dechend, R; Fiebeler, A; Hilfenhaus, G; Jeng, AY; Luft, FC; Maser-Gluth, C; Meiners, S; Muller, DN; Nussberger, J; Rong, S; Shagdarsuren, E; Webb, RL; Wellner, M, 2005)
"Renal fibrosis was evaluated through TGFbeta expression and superoxide dismutase (SOD) activity, hydroxyl radicals, O2- and total antioxidant activity were measured by spectrophotometric assay."	1.33	Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy. ( Carrizo, L; Manucha, W; Molina, H; Ruete, C; Vallés, P, 2005)
" Corresponding dosage of Losartan can also alleviate the motion capability and type I collagen content of hPSCs compared with AngII treatment and non-treatment control groups."	1.33	Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. ( Liu, WB; Wang, XP; Wu, K; Zhang, RL, 2005)
"Losartan pretreated-rats presented diminished FN abundance in homogenates of cortex tissue from ischemic rats with or without reperfusion."	1.32	Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. ( Barrilli, A; Elías, MM; Menacho, M; Molinas, S; Petrini, G, 2004)
"Tubulointerstitial fibrosis is considered to be common endpoint result of many forms of chronic renal diseases."	1.31	Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. ( Dai, C; Liu, Y; Yang, J, 2002)
"Compared with WKY, SHR exhibited left ventricular hypertrophy, increased (P<0."	1.31	Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. ( Díez, J; Etayo, JC; Iraburu, MJ; López, B; Varela, M; Varo, N, 2000)
"Aldosterone levels were not significantly elevated, suggesting direct proliferative effects of Ang II."	1.30	Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. ( Gray, GA; Kenyon, CJ; McEwan, PE; Sherry, L; Webb, DJ, 1998)
" This dose of losartan shifted the in vivo dose-response curve of the angiotensin II-induced elevation of left ventricular systolic pressure (LVSP) to the right."	1.30	Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats. ( Baba, HA; Bauer, M; Irlbeck, M; Iwai, T; Schmid, KW; Zimmer, HG, 1999)
"Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure."	1.29	Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995)

Research

Studies (183)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Change in CD4+ Cell Count From Baseline to 12 Months.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	16 (8.74)	18.2507
2000's	58 (31.69)	29.6817
2010's	74 (40.44)	24.3611
2020's	35 (19.13)	2.80

Authors	Studies
Toba, H	1
Ikemoto, MJ	1
Kobara, M	1
Nakata, T	1
Castoldi, G	2
Carletti, R	2
Ippolito, S	1
Stella, A	2
Zerbini, G	2
Pelucchi, S	1
Zatti, G	1
di Gioia, CRT	1
Sampaio, LP	4
Hilgert, GSL	4
Shiju, TM	4
Murillo, SE	1
Santhiago, MR	4
Wilson, SE	6
Askaripour, M	1
Najafipour, H	1
Saberi, S	1
Jafari, E	1
Rajabi, S	1
Kuźmiuk-Glembin, I	1
Heleniak, Z	1
Pięta, R	1
Głyda, M	1
Lizakowski, S	1
Renke, M	1
Konopa, J	1
Chamienia, A	2
Biedunkiewicz, B	2
Rutkowski, B	2
Tylicki, L	2
Dębska-Ślizień, A	1
Dorotea, D	2
Jiang, S	2
Pak, ES	1
Son, JB	1
Choi, HG	1
Ahn, SM	1
Ha, H	2
Feng, R	1
Wan, J	1
He, Y	3
Gong, H	1
Xu, Z	2
Feng, J	1
Zou, J	1
Zhou, X	1
Ma, Y	2
Yu, R	1
Zhu, H	1
Ji, H	1
Chen, W	1
Han, L	1
Yu, L	1
Pereira-Souza, AL	1
Ambrósio, R	1
Bandeira, F	1
Salomão, MQ	1
Souza Lima, A	1
Sriwatananukulkit, O	2
Desclaux, S	2
Tawonsawatruk, T	2
Srikuea, R	2
Himakhun, W	2
Likitnukul, S	2
Hemstapat, R	2
Motherwell, JM	1
Dolan, CP	1
Kanovka, SS	1
Edwards, JB	1
Franco, SR	1
Janakiram, NB	1
Valerio, MS	1
Goldman, SM	1
Dearth, CL	1
Khazaeli, M	1
Nunes, ACF	1
Zhao, Y	1
Khazaali, M	1
Prudente, J	1
Vaziri, ND	1
Singh, B	1
Lau, WL	1
Liu, B	1
Jie, X	1
Deng, J	1
Zhang, S	1
Lu, F	1
Liu, X	3
Zhang, D	1
Martínez-Arias, L	1
Fernández-Villabrille, S	1
Alonso-Montes, C	1
García-Navazo, G	1
Ruíz-Torres, MP	1
Alajarín, R	1
Alvarez-Builla, J	1
Gutiérrez-Calabres, E	1
Vaquero-López, JJ	1
Carrillo-López, N	1
Rodríguez-Puyol, D	1
Cannata-Andía, JB	1
Panizo, S	1
Naves-Díaz, M	1
Lacheta, L	1
Gao, X	4
Miles, JW	1
Murata, Y	1
Fukase, N	1
Utsunomiya, H	3
Dornan, G	1
Tashman, S	1
Kashyap, R	1
Altintas, B	1
Ravuri, S	2
Philippon, M	1
Huard, J	4
Millett, PJ	1
Wei, X	1
Jin, J	1
Wu, J	1
Guo, J	2
Yang, Z	1
Chen, L	1
Hu, K	1
Li, L	2
Jia, M	1
Li, Q	2
Lv, X	1
Ge, F	1
Ma, S	1
Wu, H	1
Zhi, X	1
Wang, X	1
Jiang, L	1
Osto, E	1
Zhang, J	2
Meng, D	1
Huang, Z	1
Nie, H	1
Liu, G	1
Li, P	2
Peng, YH	1
Xiao, J	1
Gu, W	1
Li, TS	1
Song, J	1
Xia, Y	1
Yan, X	1
Luo, J	1
Jiang, C	1
Zhang, M	2
Shi, GP	1
Zhu, W	1
Eslahi, A	1
Shirazi, M	1
Khoshnood, O	1
Noorafshan, A	1
Karbalay-Doust, S	1
Baranowski, A	1
Schlemmer, L	1
Förster, K	1
Slotina, E	1
Mickan, T	1
Truffel, S	1
Klein, A	1
Mattyasovszky, SG	1
Hofmann, A	1
Ritz, U	1
Rommens, PM	1
Tawfik, VL	1
Quarta, M	1
Paine, P	1
Forman, TE	1
Pajarinen, J	1
Takemura, Y	1
Goodman, SB	1
Rando, TA	2
Clark, JD	1
da Silva-Bertani, DCT	1
Vileigas, DF	1
Mota, GAF	1
de Souza, SLB	1
Sant'Ana, PG	1
Freire, PP	1
de Tomasi, LC	1
Corrêa, CR	1
Padovani, CR	1
Fernandes, T	1
de Oliveira, EM	1
Cicogna, AC	1
Li, S	2
Li, Y	2
Zhang, Y	4
Jin, F	1
Wei, Z	1
Yang, Y	2
Mao, N	1
Ge, X	1
Xu, H	1
Yang, F	1
Nakama, GY	1
Gonzalez, S	1
Matre, P	1
Mu, X	1
Whitney, KE	1
Arner, JW	1
Philippon, MJ	2
Oh, DS	1
Son, E	1
Kim, DS	1
Baker, JV	1
Wolfson, J	1
Collins, G	1
Morse, C	1
Rhame, F	1
Liappis, AP	1
Rizza, S	1
Temesgen, Z	1
Mystakelis, H	1
Deeks, S	1
Neaton, J	1
Schacker, T	1
Sereti, I	1
Tracy, RP	1
He, YL	1
Wen, JG	1
Pu, QS	1
Wen, YB	1
Zhai, RQ	1
Chen, Y	2
Liu, EP	1
Xing, D	1
Ji, FP	1
Yang, XH	1
Wang, QW	1
Wang, Y	6
Bauer, SB	1
Akazawa, Y	1
Fujioka, T	1
Ide, H	1
Yazaki, K	1
Honjo, O	2
Sun, M	3
Friedberg, MK	2
Wang, EY	1
Kuzmanov, U	1
Smith, JB	1
Dou, W	1
Rafatian, N	1
Lai, BFL	1
Lu, RXZ	1
Wu, Q	1
Yazbeck, J	1
Zhang, XO	1
Sun, Y	4
Gramolini, A	1
Radisic, M	1
Leite, APO	1
Li, XC	1
Hassan, R	1
Zheng, X	1
Alexander, B	1
Casarini, DE	2
Zhuo, JL	1
Torres, B	1
Guardo, AC	1
Squarcia, M	1
Diaz, A	1
Fabra, A	1
Caballero, M	1
Ugarte, A	1
Leal, L	1
Gatell, JM	1
Plana, M	1
Garcia, F	1
García-Martín, A	1
Navarrete, C	1
Garrido-Rodríguez, M	1
Prados, ME	1
Caprioglio, D	1
Appendino, G	1
Muñoz, E	1
Awazu, M	1
Yamada, M	1
Asada, N	1
Hashiguchi, A	1
Kosaki, K	1
Matsumura, K	1
McPherson, S	1
Wilkinson, N	1
Tiniakos, D	1
Wilkinson, J	1
Burt, AD	1
McColl, E	1
Stocken, DD	1
Steen, N	1
Barnes, J	1
Goudie, N	1
Stewart, S	1
Bury, Y	1
Mann, D	1
Anstee, QM	1
Day, CP	1
Li, WJ	1
Xu, M	1
Gu, M	1
Zheng, DC	1
Cai, Z	1
Wang, Z	2
Bartko, PE	1
Dal-Bianco, JP	1
Guerrero, JL	1
Beaudoin, J	1
Szymanski, C	1
Kim, DH	1
Seybolt, MM	1
Handschumacher, MD	1
Sullivan, S	1
Garcia, ML	1
Titus, JS	1
Wylie-Sears, J	1
Irvin, WS	1
Messas, E	1
Hagège, AA	1
Carpentier, A	1
Aikawa, E	1
Bischoff, J	1
Levine, RA	1
Song, LJ	1
Xiang, F	1
Ye, H	1
Huang, H	1
Yang, J	2
Yu, F	1
Xiong, L	1
Xu, JJ	1
Greer, PA	1
Shi, HZ	1
Xin, JB	1
Su, Y	1
Ma, WL	1
Gu, X	1
Xu, D	1
Fu, L	1
Mei, C	1
Nelson, JW	1
Ferdaus, MZ	1
McCormick, JA	1
Minnier, J	1
Kaul, S	1
Ellison, DH	1
Barnes, AP	1
Ongali, B	1
Nicolakakis, N	1
Tong, XK	1
Lecrux, C	1
Imboden, H	1
Hamel, E	1
Walton, SL	1
Mazzuca, MQ	1
Tare, M	1
Parkington, HC	1
Wlodek, ME	1
Moritz, KM	1
Gallo, LA	1
Hosseinian, S	1
Ebrahimzadeh Bideskan, A	1
Shafei, MN	1
Sadeghnia, HR	1
Soukhtanloo, M	1
Shahraki, S	1
Samadi Noshahr, Z	1
Khajavi Rad, A	1
Bolia, I	1
Briggs, K	1
Lowe, WR	1
Koszegi, S	1
Molnar, A	1
Lenart, L	1
Hodrea, J	1
Balogh, DB	1
Lakat, T	1
Szkibinszkij, E	1
Hosszu, A	1
Sparding, N	1
Genovese, F	1
Wagner, L	1
Vannay, A	1
Szabo, AJ	1
Fekete, A	1
Leenen, FHH	1
Ahmad, M	1
Marc, Y	1
Llorens-Cortes, C	1
Nafar, M	1
Samavat, S	1
Shahraki, E	1
Choi, JA	1
Kim, JE	1
Ju, HH	1
Lee, J	1
Jee, D	1
Park, CK	1
Paik, SY	1
Poletto Bonetto, JH	1
Fernandes, RO	1
Dartora, DR	1
Flahault, A	1
Sonea, A	1
Cloutier, A	1
Belló-Klein, A	1
Nuyt, AM	1
Kusunoki, H	1
Taniyama, Y	1
Rakugi, H	1
Morishita, R	1
Kim, HS	1
No, CW	1
Goo, SH	1
Cha, TJ	1
Cho, MY	2
Li, J	1
Assad, RS	1
Rohailla, S	1
Apitz, C	1
Redington, AN	1
Qin, J	1
Xie, YY	1
Huang, L	1
Yuan, QJ	1
Mei, WJ	1
Yuan, XN	1
Hu, GY	1
Cheng, GJ	1
Tao, LJ	1
Peng, ZZ	1
Issa, N	1
Ortiz, F	1
Reule, SA	1
Kukla, A	1
Kasiske, BL	1
Mauer, M	2
Jackson, S	2
Matas, AJ	1
Ibrahim, HN	2
Najafian, B	2
Stuckey, DJ	1
McSweeney, SJ	1
Thin, MZ	1
Habib, J	1
Price, AN	1
Fiedler, LR	1
Gsell, W	1
Prasad, SK	1
Schneider, MD	1
Arnoni, CP	1
Maquigussa, E	1
Passos, CS	1
Pereira, LG	1
Boim, MA	1
Shimada, YJ	1
Passeri, JJ	1
Baggish, AL	1
O'Callaghan, C	1
Lowry, PA	1
Yannekis, G	1
Abbara, S	1
Ghoshhajra, BB	1
Rothman, RD	1
Ho, CY	1
Januzzi, JL	1
Seidman, CE	2
Fifer, MA	1
He, P	1
Li, D	2
Zhang, B	1
Rosendahl, A	1
Niemann, G	1
Lange, S	1
Ahadzadeh, E	1
Krebs, C	1
Contrepas, A	1
van Goor, H	1
Wiech, T	1
Bader, M	1
Schwake, M	1
Peters, J	1
Stahl, R	1
Nguyen, G	1
Wenzel, UO	1
di Gioia, CR	1
Bombardi, C	1
Maestroni, S	1
Steckelings, UM	1
Dahlöf, B	2
Unger, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial[NCT02049307]	Phase 2	108 participants (Actual)	Interventional	2014-10-16	Completed
A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216]	Phase 2	40 participants (Anticipated)	Interventional	2023-08-17	Recruiting
Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients[NCT00067990]	Phase 4	153 participants (Actual)	Interventional	2002-12-31	Completed
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy[NCT01150461]	Phase 2	20 participants (Actual)	Interventional	2007-02-28	Completed
Clinical and Genetic Determinants of Disease Progression and Response to Lifestyle and Pharmacological Interventions in Patients With Hypertrophic Cardiomyopathy[NCT05366101]	Phase 2/Phase 3	168 participants (Actual)	Interventional	2019-04-01	Completed
Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy[NCT03832660]	Phase 2	168 participants (Actual)	Interventional	2019-05-03	Completed
INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.[NCT01447654]	Phase 2	130 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation[NCT05285878]	Phase 2	20 participants (Anticipated)	Interventional	2022-07-28	Enrolling by invitation
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260]	Phase 3	496 participants (Actual)	Interventional	1995-06-30	Completed
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)[NCT03317925]		29 participants (Actual)	Observational	2014-07-16	Completed
Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124]	Phase 3	291 participants (Anticipated)	Interventional	2008-07-31	Recruiting
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060]	Phase 4	53 participants (Actual)	Interventional	2007-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in cluster of differentiation 4 (CD4+) cell count from baseline to 12 months (NCT02049307)
Timeframe: Baseline and 12 months

Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 12 Months

Intervention	Cells/mm^3 (Mean)
Treatment (Losartan)	15.1
Placebo	6.8

Difference between treatment and control IL-6 plasma levels from pre-treatment to on-treatment values (NCT02049307)
Timeframe: Baseline and 12 months

Doubling of Interstitium or Any ESRD

Intervention	pg/mL (Mean)
Treatment	0.14
Placebo	0.29

Doubling of the interstitial or any defined ESRD (including IF/TA) (NCT00067990)
Timeframe: Baseline to 5 years

Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD

Intervention	Participants (Count of Participants)
Losartan	6
Placebo	12

Number of subjects who had doubling of the interstitial or any end stage renal disease (ESRD) not attributed to interstitial fibrosis and tubular atrophy (IF/TA) (NCT00067990)
Timeframe: Baseline and 5 Years Post Transplant

Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging.

Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging.

Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo.

Intervention	Participants (Count of Participants)
Losartan	7
Placebo	15

Intervention	Percentage change in fibrotic myocardium (Mean)
Losartan 50 mg PO BID	-23
Placebo	31

Intervention	Percentage change in LV mass (Mean)
Losartan 50 mg PO BID	-5
Placebo	5

Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Left Atrial Dimension (in mm)

Intervention	micrograms/L (Mean)
	Baseline (PINP)	12 Months (PINP)	Baseline (PIIINP)	12 Months (PIIINP)	Baseline (ICTP)	12 Months (ICTP)
Placebo Control	2.1	0.6	4.5	1.6	2.5	-2.3
Spironolactone	2.1	0.7	4.7	2.0	2.2	2.7

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Left Ventricular End-Diastolic (LVED) Cavity Size (in mm/m^2)

Intervention	millimeters (Mean)
	Left Atrial Dimension (Baseline)	Left Atrial Dimension (12-Month Follow-Up)
Placebo Control	41	40
Spironolactone	40	40

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Maximum Left Ventricular Wall Thickness (in mm)

Intervention	mm/m^2 (Mean)
	LVED Cavity Size (Baseline)	LVED Cavity Size (12-Month Follow-Up)
Placebo Control	145	146
Spironolactone	133	129

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Percentage of Left Ventricular Mass (%LV)

Intervention	millimeters (Mean)
	Maximum Left Ventricular Wall Thickness (Baseline)	Maximum Left Ventricular Wall Thickness (12-Month Follow-Up)
Placebo Control	21	19
Spironolactone	22	22

Measure of Functional Capacity: Peak Oxygen Consumption With Exercise

Intervention	Percentage of Total LV Mass (Mean)
	LGE Assessment of Myocardial Fibrosis (Baseline)	LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up)
Placebo Control	2.5	2.8
Spironolactone	1.1	1.8

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

Measure of Heart Failure Symptoms According to the New York Heart Association Functional Class

Intervention	ml/kg/min (Mean)
	Peak VO2 (Baseline)	Peak VO2 (12-Month Follow-Up)
Placebo Control	28	29
Spironolactone	30	29

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)

Measure of Indices of Diastolic Function by Tissue Doppler Echocardiography (Septal E/e')

Intervention	score on a scale (Mean)
	NYHA Class (Baseline)	NYHA Class (12-Month Follow Up)
Placebo Control	1.5	1.6
Spironolactone	1.6	1.7

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

Article	Year
Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive rats. European journal of pharmacology, 2022, Jan-05, Volume: 914 Topics: ADAMTS1 Protein; Angiotensin II Type 1 Receptor Blockers; Animals; Desoxycorticosterone Acetate; Ext	2022
Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension. International journal of molecular sciences, 2021, Dec-20, Volume: 22, Issue:24 Topics: Angiotensin I; Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Hypertension	2021
Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. Experimental eye research, 2022, Volume: 216 Topics: Actins; Administration, Ophthalmic; Angiotensin II Type 1 Receptor Blockers; Animals; Cicatrix; Coll	2022
Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. Iranian journal of kidney diseases, 2022, Volume: 1, Issue:1 Topics: Aged; Animals; Antioxidants; Female; Fibrosis; Humans; Inflammation; Isoflavones; Kidney; Losartan;	2022
Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. Translational vision science & technology, 2022, 07-08, Volume: 11, Issue:7 Topics: Adrenal Cortex Hormones; Alkalies; Animals; Burns, Chemical; Cicatrix; Collagen Type IV; Corneal Dis	2022
Pan-Src kinase inhibitor treatment attenuates diabetic kidney injury via inhibition of Fyn kinase-mediated endoplasmic reticulum stress. Experimental & molecular medicine, 2022, Volume: 54, Issue:8 Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fibr	2022
Angiotensin-receptor blocker losartan alleviates atrial fibrillation in rats by downregulating frizzled 8 and inhibiting the activation of WNT-5A pathway. Clinical and experimental pharmacology & physiology, 2023, Volume: 50, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; A	2023
Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 149 Topics: Animals; Fibrosis; Kidney; Kidney Diseases; Losartan; Male; Metabolic Networks and Pathways; Mice; M	2022
Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis. Archives of biochemistry and biophysics, 2022, 11-15, Volume: 730 Topics: Angiotensin II; Animals; Cardiomyopathies; Extracellular Matrix Proteins; Fibroblasts; Fibrosis; Int	2022
Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:11 Topics: Adult; Corneal Diseases; Corneal Opacity; Corneal Stroma; Female; Fibrosis; Humans; Keratomileusis,	2022
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:12 Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United Stat	2022
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:12 Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United Stat	2022
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:12 Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United Stat	2022
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:12 Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United Stat	2022
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158 Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta	2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158 Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta	2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158 Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta	2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158 Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta	2023
Effects of Adjunct Antifibrotic Treatment within a Regenerative Rehabilitation Paradigm for Volumetric Muscle Loss. International journal of molecular sciences, 2023, Feb-10, Volume: 24, Issue:4 Topics: Animals; Fibrosis; Losartan; Medicine; Motor Activity; Muscle, Skeletal; Muscular Diseases	2023
Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. Pharmacology research & perspectives, 2023, Volume: 11, Issue:2 Topics: Animals; Antioxidants; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies	2023
Bupi Yishen formula may prevent kidney fibrosis by modulating fatty acid metabolism in renal tubules. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 114 Topics: Animals; Fatty Acids; Fibrosis; Humans; Kidney; Losartan; Rats; Renal Insufficiency, Chronic	2023
Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure. Nutrients, 2023, Apr-10, Volume: 15, Issue:8 Topics: Animals; Antioxidants; Fibrosis; Kidney; Kidney Failure, Chronic; Losartan; Male; Models, Theoretica	2023
Losartan in Combination With Bone Marrow Stimulation Showed Synergistic Effects on Load to Failure and Tendon Matrix Organization in a Rabbit Model. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2023, Volume: 39, Issue:12 Topics: Animals; Bone Marrow; Collagen Type I; Collagen Type III; Fibrosis; Losartan; Rabbits; Tendons; Tran	2023
Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway. Cardiovascular research, 2023, 08-07, Volume: 119, Issue:9 Topics: Angiotensin II; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly;	2023
Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. Archives of biochemistry and biophysics, 2023, 10-15, Volume: 748 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Epithelial Cell	2023
Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs. International urology and nephrology, 2019, Volume: 51, Issue:11 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Fibrosis; Kidney; Losartan; Male; Mice; Mice, Inb	2019
Comparison of the effects of pentoxifylline, simvastatin, tamoxifen, and losartan on cavernous bodies after penile fracture in rats: a stereological study. International journal of impotence research, 2020, Volume: 32, Issue:3 Topics: Animals; Fibrosis; Losartan; Male; Penile Diseases; Pentoxifylline; Rats; Simvastatin; Tamoxifen	2020
Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model. Drug design, development and therapy, 2019, Volume: 13 Topics: Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Joint Capsule; Knee Injuries; Knee Joint; L	2019
Angiotensin receptor blockade mimics the effect of exercise on recovery after orthopaedic trauma by decreasing pain and improving muscle regeneration. The Journal of physiology, 2020, Volume: 598, Issue:2 Topics: Angiotensin Receptor Antagonists; Animals; Fibrosis; Fractures, Bone; Hyperalgesia; Losartan; Mice;	2020
Increased angiotensin II from adipose tissue modulates myocardial collagen I and III in obese rats. Life sciences, 2020, Jul-01, Volume: 252 Topics: Adipose Tissue; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Collagen Type I; C	2020
N-Acetyl-Seryl-Asparyl-Lysyl-Proline regulates lung renin angiotensin system to inhibit epithelial-mesenchymal transition in silicotic mice. Toxicology and applied pharmacology, 2020, 12-01, Volume: 408 Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym	2020
Effect of Oral Losartan on Orthobiologics: Implications for Platelet-Rich Plasma and Bone Marrow Concentrate-A Rabbit Study. International journal of molecular sciences, 2020, Oct-06, Volume: 21, Issue:19 Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Bon	2020
Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 80 Topics: Animals; Cell Line; Collagen Type I; Drugs, Chinese Herbal; Fibronectins; Fibrosis; Kidney Diseases;	2021
Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder. Neurourology and urodynamics, 2021, Volume: 40, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibrosis; Losartan; Male;	2021
Impaired right and left ventricular function and relaxation induced by pulmonary regurgitation are not reversed by tardive antifibrosis treatment. American journal of physiology. Heart and circulatory physiology, 2021, 07-01, Volume: 321, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography; Fibrosis	2021
An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy. Journal of molecular and cellular cardiology, 2021, Volume: 160 Topics: Angiotensin II; Animals; Cardiomyopathies; Cardiotonic Agents; Cell Line; Cell Survival; Coculture T	2021
Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. Clinical science (London, England : 1979), 2021, 08-13, Volume: 135, Issue:15 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial	2021
EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 142 Topics: Administration, Oral; Angiotensin II; Animals; Anti-Inflammatory Agents; Cannabidiol; Fibroblasts; F	2021
A girl with a mutation of the ciliary gene CC2D2A presenting with FSGS and nephronophthisis. CEN case reports, 2022, Volume: 11, Issue:1 Topics: Child; Child, Preschool; Cytoskeletal Proteins; Female; Fibrosis; Glomerulosclerosis, Focal Segmenta	2022
Losartan Preserves Erectile Function by Suppression of Apoptosis and Fibrosis of Corpus Cavernosum and Corporal Veno-Occlusive Dysfunction in Diabetic Rats. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 42, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Collagen; Cyclic GMP; Diabetes Mellitu	2017
Effect of Losartan on Mitral Valve Changes After Myocardial Infarction. Journal of the American College of Cardiology, 2017, Sep-05, Volume: 70, Issue:10 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography, Three-Di	2017
Inhibition of angiotensin II and calpain attenuates pleural fibrosis. Pulmonary pharmacology & therapeutics, 2018, Volume: 48 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bleomycin; Calpain; Carbon; Cell L	2018
KLF 15 Works as an Early Anti-Fibrotic Transcriptional Regulator in Ang II-Induced Renal Fibrosis via Down-Regulation of CTGF Expression. Kidney & blood pressure research, 2017, Volume: 42, Issue:6 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Connective Tissue Growth Factor; D	2017
Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension. Physiological genomics, 2018, 02-01, Volume: 50, Issue:2 Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Fibrosis; Hea	2018
Transforming growth factor-β1 induces cerebrovascular dysfunction and astrogliosis through angiotensin II type 1 receptor-mediated signaling pathways. Canadian journal of physiology and pharmacology, 2018, Volume: 96, Issue:5 Topics: Animals; Brain; Enalapril; Female; Fibrosis; Gliosis; Losartan; Male; Mice; Mice, Transgenic; Recept	2018
Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health. Pharmacological research, 2018, Volume: 134 Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Birth Weight; Blood	2018
Nigella sativa extract is a potent therapeutic agent for renal inflammation, apoptosis, and oxidative stress in a rat model of unilateral ureteral obstruction. Phytotherapy research : PTR, 2018, Volume: 32, Issue:11 Topics: Angiotensin II; Animals; Apoptosis; Captopril; Chemokine CCL2; Creatinine; Fibrosis; Inflammation; K	2018
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. The Journal of physiology, 2019, Volume: 597, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Lin	2019
Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. Journal of cardiovascular pharmacology, 2019, Volume: 73, Issue:2 Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Animals; Brain; Dise	2019
The effects of losartan on cytomegalovirus infection in human trabecular meshwork cells. PloS one, 2019, Volume: 14, Issue:6 Topics: Actins; Connective Tissue Growth Factor; Cytomegalovirus; Cytomegalovirus Infections; Enzyme-Linked	2019
Impact of early life AT European journal of pharmacology, 2019, Oct-05, Volume: 860 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Biomarkers; Cardiomyopathies; Di	2019
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension. Journal of the American Heart Association, 2013, Apr-22, Volume: 2, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithe	2013
An Angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model. Journal of Korean medical science, 2013, Volume: 28, Issue:5 Topics: Angiotensin Receptor Antagonists; Animals; Atrial Fibrillation; Atrial Remodeling; Disease Models, A	2013
Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-β1 signaling and is abrogated by angiotensin receptor blockade. American journal of respiratory cell and molecular biology, 2013, Volume: 49, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Connective Tissue Growth Factor; Endoth	2013
Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. Nephrology (Carlton, Vic.), 2013, Volume: 18, Issue:10 Topics: Angiotensin II; Animals; Antioxidants; Cell Line; Class Ia Phosphatidylinositol 3-Kinase; Collagen T	2013
T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. Circulation. Cardiovascular imaging, 2014, Volume: 7, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Contrast Media; Disease Models, Animal; Dose-Respo	2014
Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:3 Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cell Movement; Cell Transdifferentiation; Chole	2015
Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. Molecular medicine reports, 2014, Volume: 10, Issue:2 Topics: Actins; Animals; Apoptosis; bcl-2-Associated X Protein; Collagen Type I; Dimethyl Sulfoxide; Disease	2014
Increased expression of (pro)renin receptor does not cause hypertension or cardiac and renal fibrosis in mice. Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:8 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fibrosis; Heart Ventricles; H	2014
Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. American journal of physiology. Renal physiology, 2014, Nov-15, Volume: 307, Issue:10 Topics: Albuminuria; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug	2014
Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. Journal of applied physiology (Bethesda, Md. : 1985), 2014, Nov-15, Volume: 117, Issue:10 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Dose-Response Relationship	2014
Profibrosing effect of angiotensin converting enzyme inhibitors in human lung fibroblasts. Lung, 2015, Volume: 193, Issue:2 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril	2015
Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation. American journal of physiology. Gastrointestinal and liver physiology, 2015, Apr-15, Volume: 308, Issue:8 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bile Ducts, Extrahepatic; Cell Lin	2015
The role of KCa3.1 channels in cardiac fibrosis induced by pressure overload in rats. Pflugers Archiv : European journal of physiology, 2015, Volume: 467, Issue:11 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Aorta, Abdominal; Blood Pressure;	2015
TRIF promotes angiotensin II-induced cross-talk between fibroblasts and macrophages in atrial fibrosis. Biochemical and biophysical research communications, 2015, Aug-14, Volume: 464, Issue:1 Topics: Adaptor Proteins, Vesicular Transport; Angiotensin II; Animals; Atrial Fibrillation; Cell Communicat	2015
Quiz page: an unusual cause of nephrotic syndrome. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 66, Issue:1 Topics: Antihypertensive Agents; Collagen Diseases; Collagen Type III; Edema; Fibrosis; Humans; Hypertension	2015
Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by AT-1R antagonism. Kidney international, 2015, Volume: 88, Issue:4 Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultur	2015
Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). PloS one, 2015, Volume: 10, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibrosis; Laminin; Losarta	2015
Ets-1 upregulation mediates angiotensin II-related cardiac fibrosis. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:9 Topics: Angiotensin II; Animals; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Dose-Respons	2015
May the fibrosis be with you: Is discoidin domain receptor 2 the receptor we have been looking for? Journal of molecular and cellular cardiology, 2016, Volume: 91 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Collagen; Discoidin Domain Receptors; Fibroblasts;	2016
Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 01-01, Volume: 32, Issue:1 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblast Gr	2017
Metabolomics study of renal fibrosis and intervention effects of total aglycone extracts of Scutellaria baicalensis in unilateral ureteral obstruction rats. Journal of ethnopharmacology, 2016, Nov-04, Volume: 192 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Discr	2016
Renal denervation significantly attenuates cardiorenal fibrosis in rats with sustained pressure overload. Journal of the American Society of Hypertension : JASH, 2016, Volume: 10, Issue:7 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiomyo	2016
Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats. Molecular medicine reports, 2017, Volume: 15, Issue:2 Topics: Animals; Antihypertensive Agents; Blood Pressure; DNA Methylation; Fibrosis; Hypertension; Hypertrop	2017
Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Scientific reports, 2017, 02-03, Volume: 7 Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line; Connective Tissue Growth Factor; Fibros	2017
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. Acta physiologica (Oxford, England), 2017, Volume: 220, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess	2017
Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. The American journal of sports medicine, 2008, Volume: 36, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Fibrosis; Losart	2008
N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster. Antioxidants & redox signaling, 2008, Volume: 10, Issue:12 Topics: Acetylcysteine; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Benzylamines; Cardiomyop	2008
[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:12 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Losartan; M	2008
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC. Cardiovascular imaging, 2009, Volume: 2, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri	2009
Losartan preserves erectile function after bilateral cavernous nerve injury via antifibrotic mechanisms in male rats. The Journal of urology, 2009, Volume: 181, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Erectile Dysfunction; Fibrosis; Losartan; Male; Pe	2009
Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals,	2009
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. American journal of physiology. Renal physiology, 2009, Volume: 297, Issue:3 Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Cyto	2009
Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:5 Topics: Actins; Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I	2009
Heme oxygenase-1 inducer hemin attenuates the progression of remnant kidney model. Nephron. Experimental nephrology, 2009, Volume: 113, Issue:1 Topics: Animals; Bone Morphogenetic Protein 7; Caspase 3; Disease Progression; Enzyme Induction; Fibrosis; G	2009
Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Urea Nitrogen; Blotting, Western; Cardiomyop	2009
Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An	2010
Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:6 Topics: Angiotensin I; Animals; Cells, Cultured; Chemokine CCL2; Collagen Type I; Connective Tissue Growth F	2010
Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 299, Issue:1 Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrophy; Ceruletide; Colla	2010
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:2 Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr	2010
Losartan reduces mortality in a genetic model of heart failure. Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 382, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 Receptor Blockers; Animals; Calsequestri	2010
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats. The Journal of nutrition, 2010, Volume: 140, Issue:10 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen	2010
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. The Journal of clinical investigation, 2010, Volume: 120, Issue:10 Topics: Animals; Bromodeoxyuridine; Cardiomyopathy, Hypertrophic; Cell Proliferation; Disease Models, Animal	2010
Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circulation research, 2011, Jan-21, Volume: 108, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Cells, Cultur	2011
Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. Journal of cardiovascular pharmacology and therapeutics, 2011, Volume: 16, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathies; Cell Adhesion Mo	2011
Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblasts. Cardiovascular research, 2011, Jul-01, Volume: 91, Issue:1 Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Adhesio	2011
Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling. Cardiovascular research, 2011, Jul-15, Volume: 91, Issue:2 Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, New	2011
Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PloS one, 2011, Volume: 6, Issue:6 Topics: Animals; Fibrosis; Heart; Heart Conduction System; Heart Function Tests; Losartan; Male; Mice; Mice,	2011
[Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:8 Topics: Animals; Chemokine CCL2; Fibrosis; Kidney; Losartan; Male; Rats; Rats, Sprague-Dawley; Transforming	2011
Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. American journal of physiology. Renal physiology, 2012, Jan-01, Volume: 302, Issue:1 Topics: Angiotensin II; Animals; Cell Degranulation; Fibrosis; Humans; In Vitro Techniques; Kidney; Kidney D	2012
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension (Dallas, Tex. : 1979), 2012, Volume: 59, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Collagen; Disease Models, A	2012
Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Colitis; Disease Models, Animal; Disease Progressi	2012
[Investigate the effects of compound radix notoginseng on renal interstitial fibrosis and kidney-targeting treatment]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2012, Volume: 43, Issue:1 Topics: Actins; Animals; Collagen Type I; Drugs, Chinese Herbal; Fibronectins; Fibrosis; Kidney; Losartan; M	2012
Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PloS one, 2012, Volume: 7, Issue:3 Topics: Angiotensinogen; Animals; Cresols; Epithelial-Mesenchymal Transition; Fibrosis; Gene Expression Regu	2012
Losartan improves adipose tissue-derived stem cell niche by inhibiting transforming growth factor-β and fibrosis in skeletal muscle injury. Cell transplantation, 2012, Volume: 21, Issue:11 Topics: Adipose Tissue; Animals; Coculture Techniques; Fibrosis; Immunoblotting; Losartan; Male; Mice; Mice,	2012
Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. Experimental cell research, 2012, Oct-01, Volume: 318, Issue:16 Topics: Angiotensin II; Animals; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Gene Expression; He	2012
The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. The Journal of steroid biochemistry and molecular biology, 2012, Volume: 132, Issue:3-5 Topics: Animals; Aorta; Atrial Natriuretic Factor; Blood Pressure; Collagen Type III; Disease Models, Animal	2012
(Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function. PloS one, 2012, Volume: 7, Issue:7 Topics: Adenoviridae; Angiotensin II; Animals; Apoptosis; Cell Proliferation; Enzyme Activation; Extracellul	2012
Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. Circulation, 2012, Sep-11, Volume: 126, Issue:11 Suppl 1 Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Cells, Cultured; Co	2012
Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation. The Journal of surgical research, 2013, Volume: 179, Issue:1 Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents;	2013
Losartan alleviates renal fibrosis by down-regulating HIF-1α and up-regulating MMP-9/TIMP-1 in rats with 5/6 nephrectomy. Renal failure, 2012, Volume: 34, Issue:10 Topics: Animals; Down-Regulation; Fibrosis; Kidney; Losartan; Male; Matrix Metalloproteinase 9; Nephrectomy;	2012
Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. PloS one, 2013, Volume: 8, Issue:2 Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, We	2013
Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. Journal of the American Society of Nephrology : JASN, 2002, Volume: 13, Issue:10 Topics: Actins; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cells, Cultured; Drug Synergism;	2002
Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. The Journal of urology, 2002, Volume: 168, Issue:4 Pt 1 Topics: Angiotensin Receptor Antagonists; Animals; Atrophy; Fibrosis; Hyperoxaluria; Kidney Tubules; Losarta	2002
Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation, 2002, Oct-01, Volume: 106, Issue:14 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blotting, Western; Diseas	2002
Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. Chinese medical journal, 2002, Volume: 115, Issue:9 Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Fibrosis; Fosinopril; H	2002
Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circulation research, 2002, Dec-13, Volume: 91, Issue:12 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Cardiomyopathies; Cells	2002
[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 2001, Apr-28, Volume: 26, Issue:2 Topics: Angiotensin II; Animals; Antihypertensive Agents; Fibrosis; Fosinopril; Hypertension; Losartan; Male	2001
Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation, 2003, Feb-15, Volume: 75, Issue:3 Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Body Weight; Chronic D	2003
Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation, 2003, Sep-23, Volume: 108, Issue:12 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Cells, Cultured; Connective Tissue	2003
Angiotensin II dependent testicular fibrosis and effects on spermatogenesis after vasectomy in the rat. The Journal of urology, 2003, Volume: 170, Issue:5 Topics: Acetylcysteine; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conv	2003
[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. Medicina, 2004, Volume: 64, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Fibrosis; Losartan; Myoca	2004
Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. Kidney international, 2004, Volume: 65, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Cyclooxygenase 2; Female; Fibrosis;	2004
Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. Molecular and cellular biochemistry, 2004, Volume: 260, Issue:1-2 Topics: Animals; Blood Urea Nitrogen; Fibronectins; Fibrosis; Glomerular Filtration Rate; Ischemia; Kidney C	2004
Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. American journal of hypertension, 2004, Volume: 17, Issue:7 Topics: Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Biomarkers; Blood Pressure; Cyclic N-Ox	2004
Contribution of angiotensin II to alcohol-induced pancreatic fibrosis in rats. The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:3 Topics: Actins; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Captopril; C	2004
Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E. American journal of physiology. Heart and circulatory physiology, 2005, Volume: 288, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cells, Cultured; Col	2005
Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet. Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:8 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; A	2004
Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R. Pancreas, 2004, Volume: 29, Issue:4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Disease Models, Animal;	2004
Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. Journal of cardiovascular pharmacology, 2005, Volume: 45, Issue:1 Topics: Adrenergic beta-Agonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anim	2005
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation, 2005, Jun-14, Volume: 111, Issue:23 Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Angiotensin II; Angiotensinogen; Animals; Animals, Genet	2005
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation, 2005, Jun-15, Volume: 79, Issue:11 Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; K	2005
Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy. Cellular and molecular biology (Noisy-le-Grand, France), 2005, Nov-08, Volume: 51, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Female; Fibrosis; Gene Expression	2005
Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. World journal of gastroenterology, 2005, Nov-07, Volume: 11, Issue:41 Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cell Division; Cell Movement; Cells, Cultured; F	2005
Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. American journal of nephrology, 2006, Volume: 26, Issue:1 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Diabetic Nephropathies; D	2006
Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. The Journal of urology, 2006, Volume: 176, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Los	2006
Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. Nephron. Experimental nephrology, 2007, Volume: 105, Issue:2 Topics: Albuminuria; Animals; Antihypertensive Agents; Benzamides; Diabetic Nephropathies; Disease Models, A	2007
Prevention of interstitial fibrosis of renal allograft by angiotensin II blockade. Transplantation proceedings, 2006, Volume: 38, Issue:10 Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cyclosporine; Female; Fibrosis; Huma	2006
Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2006, Volume: 7, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomyopathy, Dilated; Cell Communication; Crice	2006
[Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats]. The Korean journal of hepatology, 2007, Volume: 13, Issue:1 Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Bile Ducts; Captopril; Fibrosis; Hydroxypr	2007
Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. International journal of cardiology, 2008, Mar-28, Volume: 125, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Autoanti	2008
Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:5 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Benzoates;	2008
Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. European journal of pharmacology, 2008, Jun-10, Volume: 587, Issue:1-3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Calcium	2008
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:3 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biopsy; Creatinine; Femal	2008
Effect of angiotensin II blockade on the fibroproliferative response to phenylephrine in the rat heart. Hypertension (Dallas, Tex. : 1979), 1995, Volume: 25, Issue:4 Pt 2 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blotting, Nor	1995
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension (Dallas, Tex. : 1979), 1995, Volume: 26, Issue:1 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biochemical Phen	1995
Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovascular research, 1994, Volume: 28, Issue:11 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Autoradiography; Biphenyl Compounds; Coll	1994
Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. The Journal of clinical investigation, 1996, Jul-15, Volume: 98, Issue:2 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic;	1996
The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. The American journal of physiology, 1996, Volume: 271, Issue:5 Pt 1 Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Body Weight; Canr	1996
Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. The Journal of laboratory and clinical medicine, 1997, Volume: 129, Issue:4 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun	1997
Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney international, 1998, Volume: 53, Issue:4 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Argin	1998
Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. Journal of molecular and cellular cardiology, 1998, Volume: 30, Issue:8 Topics: Angiotensin II; Animals; Collagen; Fibrosis; Losartan; Male; Myocardial Infarction; Myocardium; Pept	1998
Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney international, 1998, Volume: 54, Issue:5 Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Eating; Enalapril; Fibronectins; Fibrosis; Glo	1998
Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation, 1998, Dec-15, Volume: 98, Issue:24 Topics: Aldosterone; Angiotensin II; Animals; Arterioles; Blood Pressure; Cell Division; Collagen; Coronary	1998
Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats. Journal of molecular and cellular cardiology, 1999, Volume: 31, Issue:2 Topics: Angiotensin Receptor Antagonists; Animals; Cell Size; Female; Fibrosis; Heart Ventricles; Hypertroph	1999
Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. Journal of hypertension, 1999, Volume: 17, Issue:1 Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Blotting, Northern; Cardiomyopathies;	1999
Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney international, 1999, Volume: 56, Issue:2 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Anti-Bacterial Agents; Antihypertensive Agents; Bl	1999
Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring. Circulation research, 1999, Nov-12, Volume: 85, Issue:10 Topics: Animals; Animals, Newborn; Antihypertensive Agents; Aorta; Blood Pressure; DNA, Antisense; Fibrosis;	1999
Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:6 Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Collagen; Collagenases; Extracellular Mat	2000
[Preventional intervention of myocardial interstitial fibrosis in murine myocardium with acute myocarditis]. Zhonghua yi xue za zhi, 1998, Volume: 78, Issue:9 Topics: Animals; Coxsackievirus Infections; Enterovirus B, Human; Fibrosis; Losartan; Male; Mice; Mice, Inbr	1998
Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat. Hypertension (Dallas, Tex. : 1979), 2000, Volume: 36, Issue:5 Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Diseases; Heart Ventricles; Hypertens	2000
Effect of chronic angiotensin II inhibition on the cardiovascular system of the normal rat. American journal of hypertension, 2000, Volume: 13, Issue:12 Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Body Weight; Cardiovascular System; Collagen; Cyclic	2000
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation, 2001, Feb-13, Volume: 103, Issue:6 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co	2001
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation, 2001, Feb-13, Volume: 103, Issue:6 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co	2001
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation, 2001, Feb-13, Volume: 103, Issue:6 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co	2001
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation, 2001, Feb-13, Volume: 103, Issue:6 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co	2001
Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney. Kidney international, 2001, Volume: 60, Issue:3 Topics: Angiotensin II; Animals; Apoptosis; Blood Pressure; Cyclosporine; Diet, Sodium-Restricted; Epidermal	2001
The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4. Chinese medical journal, 2001, Volume: 114, Issue:6 Topics: Alanine Transaminase; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartate A	2001
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation, 2002, Feb-12, Volume: 105, Issue:6 Topics: Aldosterone; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Bo	2002
One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. Journal of gastroenterology, 2002, Volume: 37, Issue:3 Topics: Aged; Antihypertensive Agents; Ascites; Creatinine; Female; Fibrosis; Humans; Kidney; Losartan; Male	2002
Does angiotensin II type 1 receptor blockade offer a clinical advantage to cirrhotics with ascites? Journal of gastroenterology, 2002, Volume: 37, Issue:3 Topics: Antihypertensive Agents; Ascites; Fibrosis; Humans; Losartan; Renal Plasma Flow, Effective; Sodium	2002

losartan and Cirrhosis